- Dr. Andrea Laurenzi
- Dr.ssa Amelia Caretto, Dott.ssa Alice Burini
The aim of this study is to demonstrate that an ultra-rapid formulation of insulin lispro, LY900014, is noninferior to Humalog on glycemic control as measured by change from baseline to Week 16 in HbA1c in patients with T1D
using CSII when bolus doses are delivered in a double-blind manner immediately prior to each meal via an insulin
Study I8B-MC-ITRO (ITRO) is a Phase 3, prospective, randomized, outpatient, multinational,
multicenter, 2-treatment group, parallel, active-controlled, double-blind study conducted in
patients with T1D currently using CSII therapy.
- Type 1 diabetes
- Phase 3
A prospective, randomized, double-blind comparison of LY900014 to Humalog in adults with type 1 diabetes using continuous subcutaneous insulin infusion: PRONTO-pump-2.